Nuvo Pharmaceuticals Inc
TSX:MRV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (1), the stock would be worth CA$1.35 (0% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 | CA$1.35 |
0%
|
| 3-Year Average | 1 | CA$1.35 |
0%
|
| 5-Year Average | 1 | CA$1.35 |
0%
|
| Industry Average | 10.4 | CA$14.12 |
+946%
|
| Country Average | 10.9 | CA$14.94 |
+1 007%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
15.4m CAD | 1 | 1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 49.3 | 40.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 22.1 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 19.7 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 14.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 16.7 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 13 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.3 | 16.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 7.2 |
| Median | 10.9 |
| 70th Percentile | 17 |
| Max | 26 053.9 |
Other Multiples
Nuvo Pharmaceuticals Inc
Glance View
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. The company is headquartered in Mississauga, Ontario and currently employs 100 full-time employees. The firm is engaged in offering diversified portfolio of commercial products. The company operates through three segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment is comprised of products commercialized by the Company in Canada. The company includes products, such as Blexten, Cambia, Suvexx and NeoVisc, as well as mature products. The Production and Service Business segment includes sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the revenue by the licensing of intellectual property and ongoing royalties from licensing agreements with partners.
